Stem Cell Therapeutics Corp. (SCT)) has been issued two corresponding patents to strengthen its intellectual property landscape through United States and Australia.

Stem Cell Therapeutics Corp. (SCT)) has been issued two corresponding patents to strengthen its intellectual property landscape through United States and Australia.

The US patent, numbered 7,393,830 and entitled "Prolactin induced increase in neural stem cell numbers" was issued July 1, 2008. The Australian patent, numbered 2002325711 and entitled "Prolactin induced increase in neural stem cell numbers and therapeutical use thereof" was issued January 10, 2008. These are the first patents to issue in this patent family.

Stem Cell Therapeutics Corp. is a Canadian public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells.